Dr. Arianne Caudal is a postdoctoral fellow at the Stanford Cardiovascular Institute with research interests in cardiac metabolism, disease modeling, and drug discovery. Dr. Caudal received her PhD in Biochemistry from the University of Washington, after conducting thesis work on mitochondrial metabolism and protein-protein interactions in the heart.

Honors & Awards

  • Postdoctoral Fellowship, American Heart Association (2022)
  • Postdoctoral Seed Grant, Cambridge Isotopes (2022)
  • TRAM Pilot Grant, Stanford University (2022)
  • SUMS Training Seed Award, Stanford University (2021)
  • Three Minute Thesis People's Choice Award, University of Washington (2021)
  • Predoctoral Fellowship, American Heart Association (2020-2022)
  • First Place Cover Design Contest, Journal of Molecular and Cellular Cardiology (2020)
  • ISHR World Congress Travel Award, International Society for Heart Research (2019)

Professional Education

  • Doctor of Philosophy, University of Washington (2021)
  • Bachelor of Science, University of California Santa Barbara (2014)

Stanford Advisors

All Publications

  • Generation of human induced pluripotent stem cell lines carrying heterozygous PLN mutation from dilated cardiomyopathy patients. Stem cell research Caudal, A., Mondejar-Parreno, G., Vera, C. D., Williams, D. R., Shenoy, S. P., Liang, D., Wu, J. C. 2022; 63: 102855


    Familial dilated cardiomyopathy (DCM) is among the most prevalent forms of inherited heart disease. Here, two human-induced pluripotent stem cell (iPSC) lines were generated from peripheral blood mononuclear cells (PBMCs) from DCM patients carrying different mutations in the phospholamban encoding-gene (PLN). Both iPSC lines exhibited normal morphology, karyotype, pluripotency marker expression, and differentiation into the three germ layers. These patient-specific iPSC lines serve as valuable in vitro models for DCM pathology caused by PLN mutations.

    View details for DOI 10.1016/j.scr.2022.102855

    View details for PubMedID 35853412

  • Human Induced Pluripotent Stem Cells for Studying Mitochondrial Diseases in the Heart. FEBS letters Caudal, A., Ren, L., Tu, C., Wu, J. C. 2022


    Mitochondrial dysfunction is known to contribute to a range of diseases, and primary mitochondrial defects strongly impact high-energy organs such as the heart. Platforms for high-throughput and human-relevant assessment of mitochondrial diseases are currently lacking, hindering the development of targeted therapies. In the past decade, human induced pluripotent stem cells (iPSCs) have become a promising technology for drug discovery in basic and clinical research. In particular, human iPSC-derived cardiomyocytes (iPSC-CMs) offer a unique tool to study a wide range of mitochondrial functions and possess the potential to become a key translational asset for mitochondrial drug development. This review summarizes mitochondrial functions and recent therapeutic discoveries, advancements, and limitations of using iPSC-CMs to study mitochondrial diseases of the heart with an emphasis on cardiac applications.

    View details for DOI 10.1002/1873-3468.14444

    View details for PubMedID 35788991